Robust analytics for a complete view of patients and treatment markets.
With accelerated approvals and regulatory focus on risk management and mitigation strategies, the need has never been greater for healthcare companies to be diligent when it comes to late-phase or peri-approval research.
Save time and improve evidence generation with linked clinical and patient-reported data.
A decision support resource for oncology market analysis, strategic planning and identifying commercial opportunities.
Identify and screen oncology development targets with breakthrough potential quickly, comprehensively and accurately.